187 related articles for article (PubMed ID: 25921232)
1. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer.
Liu Z; Luo G; Guo M; Jin K; Xiao Z; Liu L; Liu C; Xu J; Ni Q; Long J; Yu X
Pancreatology; 2015; 15(3):253-8. PubMed ID: 25921232
[TBL] [Abstract][Full Text] [Related]
2. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R
J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
5. Resection status, age and nodal involvement determine survival among patients receiving adjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Moghanaki D; Mick R; Furth EE; Sohal D; Salmon PM; Behbahani A; Morgans AK; Miller SM; Giantonio BJ; Whittington RW; Haller DG; Rosato EF; Plastaras JP
JOP; 2011 Sep; 12(5):438-44. PubMed ID: 21904068
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
[TBL] [Abstract][Full Text] [Related]
7. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sueda T
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S646-55. PubMed ID: 22086444
[TBL] [Abstract][Full Text] [Related]
10. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.
Kim Y; Squires MH; Poultsides GA; Fields RC; Weber SM; Votanopoulos KI; Kooby DA; Worhunsky DJ; Jin LX; Hawkins WG; Acher AW; Cho CS; Saunders N; Levine EA; Schmidt CR; Maithel SK; Pawlik TM
Surgery; 2017 Aug; 162(2):285-294. PubMed ID: 28578142
[TBL] [Abstract][Full Text] [Related]
11. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
[TBL] [Abstract][Full Text] [Related]
12. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
[TBL] [Abstract][Full Text] [Related]
13. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Hardacre JM; Mulcahy M; Small W; Talamonti M; Obel J; Krishnamurthi S; Rocha-Lima CS; Safran H; Lenz HJ; Chiorean EG
J Gastrointest Surg; 2013 Jan; 17(1):94-100; discussion p. 100-1. PubMed ID: 23229886
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG
Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637
[TBL] [Abstract][Full Text] [Related]
15. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
Lee KH; Chie EK; Im SA; Kim JH; Kwon J; Han SW; Oh DY; Jang JY; Kim JS; Kim TY; Bang YJ; Kim SW; Ha SW
Cancer Res Treat; 2021 Oct; 53(4):1096-1103. PubMed ID: 33421976
[TBL] [Abstract][Full Text] [Related]
17. Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Amano R; Kimura K; Nakata B; Yamazoe S; Motomura H; Yamamoto A; Tanaka S; Hirakawa K
Surgery; 2015 Jul; 158(1):191-200. PubMed ID: 25900035
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy.
Sherman WH; Hecht E; Leung D; Chu K
Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience.
Sainato A; Montrone S; Pasqualetti F; Coppola M; Cernusco NLV; Panichi M; Gonnelli A; Vasile E; Morganti R; Falcone A; Boggi U; Paiar F
Tumori; 2017 Nov; 103(6):577-582. PubMed ID: 28708229
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]